Here are a couple of analogies for Insight Molecular Diagnostics (IMDX):

• Like

  Exact Sciences

  , but specializing in molecular diagnostics primarily for lung cancer.
• A focused

  Guardant Health

  , developing advanced molecular tests for specific early-stage cancers like lung cancer.

• DetermaRx: A molecular test designed for early-stage adenocarcinoma of the lung.
• DetermaIO: A proprietary gene expression assay.
• Biomarker Discovery Testing: Services assisting pharmaceutical companies in identifying new biomarkers.
• Assay Design and Development: Services for creating and refining diagnostic tests.
• Clinical Trial Support Services: Support provided to pharmaceutical companies for their clinical trials.
• Biomarker Tests for Pharmaceutical Companies: Various specialized biomarker tests offered to pharmaceutical partners.

Insight Molecular Diagnostics (IMDX), based on the provided company description for OncoCyte Corporation, primarily sells its products and services to other companies and organizations.

Its major customers fall into the following categories:

• Pharmaceutical Companies: IMDX provides biomarker discovery testing, assay design and development, clinical trial support services, and various biomarker tests specifically for pharmaceutical companies. The provided description does not list specific pharmaceutical companies that are customers.
• Healthcare Providers and Institutions: These include hospitals, clinics, and medical practices that order IMDX's proprietary laboratory-developed tests, such as DetermaRx and DetermaIO, for the detection of cancer in their patients. The provided description does not list specific healthcare providers or institutions that are customers.

• Thermo Fisher Scientific (TMO)

Josh Riggs, President & Chief Executive Officer

Josh Riggs joined iMDx Corporation in August 2020 and was appointed Interim Chief Executive Officer in December 2022, and then President and Chief Executive Officer in February 2023. He previously served as Senior Director Business Development and General Manager, Transplant. Riggs is an experienced business leader, having been the founder and principal of Intelliger Consulting, an organization focused on consumer-driven healthcare. He also served as a principal at Bethesda Group, LLC, a consulting group assisting small and mid-stage diagnostic companies and investment groups in bringing emerging diagnostic content and platforms to market.

Andrea James, Chief Financial Officer

Andrea James was appointed Chief Financial Officer of Oncocyte (now iMDx) in June 2024. Prior to joining iMDx, she was the Chief Communications Officer and head of investor relations at Axon Enterprise, Inc. (Nasdaq: AXON), where she played a key role in the company's market capitalization growth from $1 billion to over $20 billion. She led Axon's repositioning within the investment community and established its corporate strategy function, overseeing capital stewardship, M&A, strategic partnerships, and investments, supporting over $550 million in equity capital offerings. Before Axon, she worked in a strategic investor relations role for Tesla, Inc. in 2016 and 2017. From 2009 to 2016, James was a sell-side analyst for Dougherty & Company, researching emerging technologies for institutional investors.

Ekkehard Schütz, Chief Science Officer

Ekkehard Schütz, also known as Ekke, joined iMDx in April 2021 following the acquisition of Chronix Biomedical. He is the managing director of Chronix Biomedical GmbH, a wholly-owned iMDx subsidiary, and serves as CMO for Europe. Schütz is an adjunct professor of molecular genetics and diagnostics at the Georg-August-University. His background includes training in laboratory medicine at the Department of Clinical Chemistry at the Georg-August-University of Göttingen, and he established the German subsidiary of Chronix Biomedical Inc. in 2002 as its R&D site.

Yuh-Min (Johnson) Chiang, PhD, Chief Technology Officer

Yuh-Min (Johnson) Chiang, PhD, joined iMDx Corporate in September 2021. Prior to this, he was the Chief Technology Officer at Alveo Technologies, an IVD company, where he led teams in developing the COVID-19 be. well Test, securing successful US clinical trial results, CE mark, and UK approval. He also contributed to fundraising efforts of approximately $50 million and won the XPrize Grand Award for Rapid Covid Testing Competition.

Sandra O'Donald, Senior Vice President, Business Operations

Sandra O'Donald joined iMDx Corporation in December 2019 and was appointed Senior Vice President, Business Operations, after holding roles as VP, Operations & PMO, and Director of PMO. She has over 20 years of experience in business management, strategy, operations, P&L management, commercialization, and integration. Her previous leadership positions include roles at consumer products company Georgia Pacific LLC, wastepaper recycling company Harmon Associates, and food manufacturing company Corbin Foods.

1. Regulatory Approval and Commercialization of GraftAssure: The company's core clinical business and its valuation are heavily reliant on the successful future regulatory clearance and commercialization of its kitted clinical transplant assay, GraftAssureDx (formerly GraftAssure). Insight Molecular Diagnostics is targeting an FDA submission by the end of 2025, with the goal of authorization in the first half of 2026. Any delays in the clinical trial or the FDA's de novo review process would significantly push back expected revenue generation, as its core clinical business is currently pre-revenue.
2. Financial Challenges and Cash Burn: Insight Molecular Diagnostics is confronting notable financial difficulties, including a declining gross margin and minimal revenue projections from its GraftAssureIQ until mid-2026, pending IVD clearance. The company has a "weak" financial health score and is rapidly utilizing cash, with analysts not anticipating profitability in the current year (as of early 2025). The company is burning approximately $6 million in net cash per quarter.
3. Competition and Market Adoption: The company operates in a competitive landscape within the diagnostics and pharmaceutical products industry, facing competitors such as LB Pharmaceuticals, MeiraGTx, Design Therapeutics, Larimar Therapeutics, and Allogene Therapeutics. The success of Insight Molecular Diagnostics' products, particularly its kitted assay strategy for decentralized testing, is also contingent on widespread physician adoption and obtaining sufficient insurer coverage. The U.S. transplant rejection testing market, estimated at $500 million annually, is currently dominated by a few central laboratories.

• DetermaRx (Molecular test for early-stage adenocarcinoma of the lung): The global total addressable market for DetermaRx is estimated to be approximately $500 million. This market addresses approximately 350,000 patients annually worldwide. More broadly, the global early-stage lung cancer diagnostics therapy market is projected to reach $6.5 billion by 2035, growing from an estimated $2.5 billion in 2025. The U.S. segment of this market is projected to reach $2.0 billion by 2035, from an estimated $863.3 million in 2025. Within the non-small cell lung cancer (NSCLC) diagnostics market, the molecular test segment accounted for 45.3% of the market revenue in 2025.
• DetermaIO (Proprietary gene expression assay): DetermaIO targets a multi-billion dollar addressable market in oncology diagnostics. OncoCyte's combined offering of DetermaIO and DetermaTx (a comprehensive genomic profiling test) aims to serve a total available market of $5 billion in the United States for the 1.8 million patients diagnosed with cancer annually. The global immuno-oncology (IO) market, a broader category for which DetermaIO is relevant, was estimated at USD 54.35 billion in 2025 and is projected to reach approximately USD 435.70 billion by 2035. The global gene expression analysis market, which includes gene expression assays, was valued at approximately $4.65 billion in 2025 and is projected to reach between $8.20 billion by 2032 and $11.92 billion by 2035.
• Biomarker discovery testing, assay design and development, and clinical trial support services for pharmaceutical companies:
  • Biomarker Discovery Services: The global biomarker discovery outsourcing services market was valued at around USD 13 billion in 2024 and is estimated to grow to USD 41.8 billion by 2034. Other estimates for this global market include USD 17.42 billion in 2025, reaching USD 86.74 billion by 2034, and USD 14.53 billion in 2024, projected to reach USD 41.27 billion by 2030. North America held the largest share of this market, at 43.96% in 2024.
  • Assay Design and Development Services: The global custom assay development market is projected to reach an estimated $28.6 billion by 2025. The global IVD (In Vitro Diagnostics) assay development market is projected to reach $8.39 billion by 2031.
  • Clinical Trial Support Services: The global clinical trials support services market is projected to grow from $25.2 billion in 2023 to $47.1 billion by 2032. Another estimate for this global market is USD 25.62 billion in 2025, reaching USD 47.00 billion by 2033. North America is the largest market for these services, holding approximately 45% of the global market share, with the U.S. accounting for the largest revenue share within North America in 2025.

Here are 3-5 expected drivers of future revenue growth for Insight Molecular Diagnostics (IMDX) over the next 2-3 years:

1. Commercialization and Adoption of GraftAssureDx (IVD kit) for Organ Transplant Rejection Testing: Insight Molecular Diagnostics, operating as OncoCyte Corporation, is heavily focused on delivering a regulated in-vitro diagnostic (IVD) test kit for organ transplant rejection monitoring to the market, with a target launch in mid-2026. This kit is anticipated to generate "material and self-sustaining revenue within a few years," addressing an estimated $2 billion-plus market for regulated transplant rejection testing. The company projects significant revenue growth starting in 2027 from this product.
2. Expansion of GraftAssure Customer Base and Market Share in Transplant Centers: Prior to the full IVD launch, the company is actively pursuing a "land-and-expand strategy" to drive commercial adoption of its GraftAssure research-use-only (RUO) kit and GraftAssureCore (laboratory-developed test) within transplant centers. The goal is to sign up at least 20 transplant centers by the end of 2025, which is expected to "spring load back half 2026 revenue" as these centers integrate the tests into their protocols.
3. Commercialization and Reimbursement of DetermaIO for Oncology: Insight Molecular Diagnostics anticipates commercializing its oncology product line, including the DetermaIO assay, within the next 18 months (from October 2024, placing it in early to mid-2026). DetermaIO is a proprietary gene expression assay designed to predict response to immunotherapies. The company is actively working towards securing CMS reimbursement coverage for DetermaIO, and its collaboration with Life Technologies Corporation to commercialize DetermaIO on the Ion Torrent Genexus integrated sequencer system could facilitate broader market access.
4. Extension of the GraftAssure Product Line to Other Organ Transplants: The company plans to expand its GraftAssure product offering beyond kidney transplant rejection testing to include other organs, such as heart transplant rejection testing. A recent capital raise in February 2026 provides funds specifically for research and development to support this expansion into new market segments within transplant diagnostics.

Share Issuance

• Insight Molecular Diagnostics (formerly OncoCyte Corporation) raised $57 million in equity from new and existing investors between January 2023 and March 2025.
• In February 2025, the company completed an equity offering, including a registered direct offering and a concurrent private placement, that resulted in gross proceeds of $29.1 million.
• In April 2024, Oncocyte reported receiving $15.8 million in gross proceeds from a private placement offering.

Inbound Investments

• Bio-Rad Laboratories, Inc. invested in the company and committed to providing financial support for upcoming clinical trials and commercialization assistance, leading a $29.1 million funding round in February 2025.
• From January 2023 to March 2025, the company secured $57 million in equity from various new and existing investors.

Outbound Investments

• In February 2021, the company acquired all outstanding shares of Razor Genomics, Inc., making it a wholly-owned subsidiary.
• In February 2023, the company sold approximately 70% of the equity interests of Razor Genomics, Inc.

Capital Expenditures

• Capital expenditures for the last 12 months (prior to March 11, 2026) were approximately $214,000.
• Capital expenditures for Q4 2024 were $0.2 million.
• The company has focused investments on developing manufacturable versions of assays, including DetermaIO™, VitaGraft, and DetermaCNI™, as well as software development costs for its clinical kitted product development.